Agilent Technologies invested $725 million, to double the facility in Frederick, Colorado's manufacturing capability for therapeutic nucleic acids.
A increasing number of diseases, including cancer, cardiovascular disease, rare diseases, and infectious diseases, require the use of active pharmaceutical ingredients (API), which will increase U.S. production of these ingredients.
It will also create more than 160 life science jobs in the Frederick area.
Agilent produces siRNA, antisense, and CRISPR guide RNA molecules in its Colorado manufacturing sites.
The company's therapeutic nucleic acid contract development and manufacturing organisation services offer exceptional customer service, the best oligo API material, and cGMP (Current Good Manufacturing Practices) to produce high-volume oligos affordably and successfully. This is true from early-stage clinical development to commercialization.
It is anticipated that the expansion will be finished by the end of 2026.
|US $725 million